PsA: Psoriatic Arthritis; SD: standard deviation, IQR: interquartile range; LEI: Leeds Enthesitis Index; MASEI: Madrid Sonographic Enthesitis Score; modified MASEI: MASEI with new PD scoring method (1: one spot of PD, 1.5: some spots of PD, 2: confluent signal, 3: severe signal) and without knee entheses thickness. Structural components: erosions, calcifications, structure. Inflammatory components: bursitis, thickness and PD signal. PD: Power Doppler. *P<0.01, **P<0.001 (Wilcoxon rank sum test).
Conclusions:
Inflammatory and structural changes of the enthesis measured with ultrasound are common in both unselected PsA patients and healthy volunteers, but more pronounced in established PsA patients. Rheumatology, Maasstad Hospital, Rotterdam; 5 Rheumatology, Amphia Hospital, Breda; 6 Rheumatology, Rivas Hospital, Gorinchem; 7 Rheumatology, Reumazorg Zuid West Nederland, Roosendaal; 8 Rheumatology, Sint Franciscus Gasthuis, Rotterdam; 9 Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands Background: The Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID12) has been developed to measure impact of Psoriatic Arthritis (PsA) for purposes of monitoring and clinical management. Although validated in patients with longstanding disease, data on validity and sensitivity to change in early PsA is lacking. Objectives: We aim to relate change in disease activity to change in PsAID12 score in early PsA and evaluate which PsAID domains are more likely to change. Methods: Patients with a new diagnosis of PsA were included in the Dutch southwest Early Psoriatic Arthritis cohoRt (DEPAR). For this analysis, patients that have PsAID12 (range 0-10) and Composite Psoriatic Disease Activity Index (CPDAI, range 0-15) data at two consecutive visits (i.e. 3 months apart) within the first year were included. In case multiple periods per patients were available, the first time period was chosen. The change in PsAID is compared to the change in disease activity over this period, measured with the CPDAI using Spearman's correlation coefficient. Change in score on individual domains of the PsAID was analysed in subgroups of patients that perceived improvement in health and those that perceived worsening. The SF-36 question on self-perceived change in health was used to determine these subgroups. Results: 143 unique patients had at least one period with two PsAID and CPDAI measurements (67 from baseline-3 months, 26 3-6 months, 25 6-9 months and 25 9-12 months). Mean age was 51 (SD 13.7) and 70 (49%) were male. The initial median PsAID was 3.35 (IQR 1.4-5.1) and the subsequent score was 2.25 (0.95-4.8 with a mean delta of 0.52 (P<0.01). Median first CDPAI score was 4 (2-7) and 3 (1-5) for the second with a mean delta of 0.45 (P<0.05). The difference in PsAID score was significantly but moderately correlated with the difference in CPDAI (Spearman's rho 0.267, P=0.0013). 58 patients (41%) report a better health status compared to 3 months ago. Figure 1 shows that patients with self-perceived improvement of health have the highest improvement in pain and only domains of skin problems and embarrassment/shame did not improve significantly. Patients reporting worsening of health (n=29) only have significantly lower scores in fatigue, discomfort and social domains.
Conclusions: Improvement in CPDAI disease activity is significantly but moderately associated with improvement in PsAID score, with the biggest improvement in the pain domain in patients with a self-reported improvement of health. (Table) . Improvements were seen in nail and scalp disease at Week 16, and responses continued to improve with APR treatment over 104 weeks and in pts who switched from ETN to APR (Table) . ScPGA 0 or 1 was achieved by 50.0% to 59.2% of pts across treatment arms, and mean percent improvement from baseline NAPSI score ranged from −48.1% to −51.1% (Table) ; the proportion of pts achieving NAPSI-50 response ranged from 48.6% to 65.2%. Adverse events (AEs) occurring in ≥5% of pts during Weeks 0 to 16 were diarrhea, nausea, nasopharyngitis, upper respiratory tract infection, and headache; long-term assessment by exposureadjusted incidence rates (EAIR)/100 pt-yrs showed no increase with longer-term APR exposure. No increase in EAIR/100 pt-yrs of serious AEs occurred during the APR extension phase (3.45 to 5.49, across groups) vs. Weeks 0 to 16 (PBO 0.0; ETN 7.91; APR 12.57). Changes in laboratory parameters were infrequent and transient; EAIR/100 pt-yrs remained low across groups through 104 weeks. Conclusions: APR demonstrated efficacy through Week 104 in pts who continued APR and pts who switched from PBO or ETN to APR at Week 16. The AE profile remained consistent with prolonged APR exposure, and no new safety or tolerability issues were observed through Week 104 in pts with moderate to severe plaque psoriasis.
